A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1217-1223

  Seymour, Leonard W ^a   Olliff, Simon P ^b   Poole, Christopher J ^a   De Takats, Philippa G ^a   Orme, Richard ^b   Ferry, David R ^a   Maeda, Hiroshi ^c   Konno, Toshimitsu ^c   Kerr, David J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

EPR effect; Hepatoma; Intra arterial infusion; Neocarzinostatin; SMANCS

Indexed keywords

IODINATED POPPYSEED OIL; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG RETENTION; EPIGASTRIC PAIN; FEMALE; FEVER; HEART INFARCTION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER CLEARANCE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYNCOPE; THROMBOCYTOPENIA; TUMOR REGRESSION; TUMOR VOLUME;

EID: 0031865287     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1217     Document Type: Review

References (23)

1. Maeda H, Seymour LW and Miyamoto Y: Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3: 351-362, 1992.
2. Seymour LW: Passive tumour targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.
3. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J and Duncan R: Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B 16F10 melanoma. Br J Cancer 70: 636-641, 1994.
4. Matsumura T and Maeda H: A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumouritropic accumulation or proteins and the antitumour agent SMANCS. Cancer Res 46: 6387-6392, 1986.
5. Maeda H, Ueda M, Morinaga T and Matsumoto T: Conjugation of poly(styrene-co-maleic acid) derivative to the antitumour protein neocarzinostatin: pronounced improvement in pharmacological properties. J Med Chem 29: 455-461, 1985.
6. Maeda H and Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210, 1989.
7. Vasey PA, Duncan R, Kaye SB and Cassidy J: Clinical phase I trial of PK1 (HPMA copolymer doxorubicin). Eur J Cancer 31A (Suppl. 5): 929, 1995.
8. Maeda H, Matsumoto T, Konno T, Iwai K and Ueda M: Tailormaking of protein drugs by polymer-conjugation for tumourtargeting. A brief review on SMANCS. J Protein Chem 3: 181-193, 1984.
9. Maeda H: SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Delivery Rev 6: 181-202, 1991.
10. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T and Yokayama I: Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19: 1053-1065, 1983.
11. Maeda H: Polymer conjugated macromolecular drugs for tumour-specific targeting. In: Polymeric Site-specific Pharmacotherapy. Domb AJ (ed). John Wiley & Sons Ltd., New York, pp95-116, 1994.
12. Konno T and Maeda H: Targeting chemotherapy of hepatocellular carcinoma: arterial administration of SMANCS/Lipiodol. In: Neoplasms of the Liver. Okuda K and Ishak KG (eds). Springer-Verlag, New York, pp343-352, 1987.
13. Maki S, Konno T and Maeda H: Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumour selective drug targeting with oily contrast medium. Cancer 56: 751 -757, 1985.
14. Buetow KH, Sheffield V, Murray JC and McMahon BJ: Genetic studies of primary hepatocellular carcinoma. Am J Hum Genet 49: 401-404, 1991.
15. Attali P, Prodhomme S, Pelletier G, Papoz L, Ink O, Buffet C and Etienne JP: Prognostic factors in patients with hepatocellular carcinoma - attempts for the selection of patients with prolonged survival. Cancer 59: 2108-2111, 1987.
16. Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ and Haller DG: A randomized phase II study of acivicin and 4' deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group. Amer J Clin Oncol - Canc Clin T 13: 510-515, 1990.
17. Mughal TI: The role of interferon alpha in the management of cancers - current scenario. Saudi Med J 12: 454-460, 1991.
18. De Takats PG, Kerr DJ, Poole CJ, Warren HW and McArdle CS: Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer 69: 372-378, 1994.
19. Iwai K, Maeda H and Konno T: Use of oily contrast medium for selective drug targeting to tumour: enhanced therapeutic effect and X-ray imaging. Cancer Res 44: 2115-2121, 1984.
20. Iwai K, Maeda H, Konno T, Matsumura Y, Yamashita R, Yamasaki K, Hirayama S and Miyauchi Y: Tumour targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 7: 321-328, 1987.
21. Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M and Miyauchi Y: Selective targeting of anticancer drug and simultaneous image enhancement in solid tumours by arterially administered lipid contrast medium. Cancer 54: 2367-2374, 1984.
22. Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, Harper P and Williams R: Pharmacokinetics and toxicity of intra-arterial adriamycin for hepatocellular carcinoma. J Hepatol 13: 120-127, 1991.
23. Konno T: Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 66: 1897-1903, 1990.